A Fabry disease charity organization has voiced its disappointment over Shire’s (NASDAQ:SHPGY) withdrawal of its biologics license application to treat the disease after talks broke down between the drug company and the U.S. Food and Drug Administration. Recent interactions with the FDA led Shire to believe that it would be required to conduct additional controlled […]
Shire (NASDAQ: SHPGY) has secured approval from U.S. regulators for a drug to manage symptoms of Attention Deficit and Hyperactivity Disorder in adults. Vyvanse has been approved as a maintenance treatment for ADHD. This new approval adds to the indication for Vyvanse as a treatment for ADHD in patients 6 years old and older, according […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.